OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
-15.81%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$107M
AUM Growth
+$107M
(-28%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-11.13%
Top 10 Holdings %
Top 10 Hldgs %
40.3%
Holding
64
New
7
Increased
16
Reduced
26
Closed
10
Top Buys
| 1 |
Pfizer
PFE
|
$3.26M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$2.03M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$1.72M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$930K |
| 5 |
SNR
NEW SENIOR INVESTMENT GROUP INC.
SNR
|
$927K |
Top Sells
| 1 |
iShares Biotechnology ETF
IBB
|
$10.7M |
| 2 |
Gilead Sciences
GILD
|
$2.79M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
$1.5M |
| 4 |
Xencor
XNCR
|
$1.32M |
| 5 |
Amgen
AMGN
|
$1.29M |
Sector Composition
| 1 | Healthcare | 84.87% |
| 2 | Real Estate | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$96B
| $4.93M | 3.81% | 77,100 | – | – |
|
|
MDVN
2
DELISTED
MEDIVATION, INC.
MDVN
| $4.89M | 3.78% | 106,358 +15,048 | +16% | +$692K |
|
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.87M | 3.77% | 77,593 +27,371 | +55% | +$1.72M |
|
4
Merck
MRK
$210B
| $4.76M | 3.68% | 90,000 | – | – |
|
|
5
Amgen
AMGN
$155B
| $4.08M | 3.15% | 27,184 -8,589 | -24% | -$1.29M |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $3.98M | 3.08% | 48,260 +4,390 | +10% | +$362K |
|
|
CELG
7
DELISTED
Celgene Corp
CELG
| $3.96M | 3.06% | 39,596 -8,360 | -17% | -$837K |
|
8
Nektar Therapeutics
NKTR
$568M
| $3.96M | 3.06% | 288,158 -60,425 | -17% | -$831K |
|
9
Ionis Pharmaceuticals
IONS
$6.79B
| $3.92M | 3.03% | 96,808 -5,651 | -6% | -$229K |
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.86M | 2.98% | 109,922 -17,166 | -14% | -$602K |
|
11
Incyte
INCY
$16.5B
| $3.75M | 2.9% | 51,677 +3,632 | +8% | +$263K |
|
|
ALXN
12
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $3.54M | 2.73% | 25,405 -7,564 | -23% | -$1.05M |
|
13
Illumina
ILMN
$15.8B
| $3.52M | 2.72% | 21,729 -914 | -4% | -$148K |
|
14
Alkermes
ALKS
$4.78B
| $3.5M | 2.7% | 102,277 +14,862 | +17% | +$508K |
|
15
Mettler-Toledo International
MTD
$26.8B
| $3.28M | 2.53% | 9,500 -200 | -2% | -$68.9K |
|
16
Vertex Pharmaceuticals
VRTX
$100B
| $3.27M | 2.53% | 41,137 -525 | -1% | -$41.7K |
|
|
17
Pfizer
PFE
$141B
| $3.26M | 2.52% | +110,000 | New | +$3.26M |
|
18
Regeneron Pharmaceuticals
REGN
$61.5B
| $3.22M | 2.49% | 8,929 -1,785 | -17% | -$643K |
|
|
QGENF
19
DELISTED
QIAGEN NV
QGENF
| $3.02M | 2.33% | 135,000 -25,000 | -16% | -$559K |
|
20
Biogen
BIIB
$19.4B
| $2.9M | 2.24% | 11,125 +643 | +6% | +$167K |
|
|
21
ProShares Ultra NASDAQ Biotechnology
BIB
$53.6M
| $2.64M | 2.04% | 64,462 +49,543 | +332% | +$2.03M |
|
|
EPZM
22
DELISTED
Epizyme, Inc
EPZM
| $2.3M | 1.78% | 189,564 +53,937 | +40% | +$654K |
|
23
AstraZeneca
AZN
$248B
| $2.23M | 1.72% | 79,100 +30,000 | +61% | +$845K |
|
24
Agios Pharmaceuticals
AGIO
$2.19B
| $2.07M | 1.6% | 51,000 +17,000 | +50% | +$690K |
|
25
Pacira BioSciences
PCRX
$1.2B
| $1.86M | 1.44% | 35,110 +16,000 | +84% | +$848K |
|